Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

VANDERTIE MICHELLE L

2. Date of Event Requiring Statement (MM/DD/YYYY) 3/31/2017

3. Issuer Name and Ticker or Trading Symbol

Conatus Pharmaceuticals Inc. [CNAT]

(Last) (First) (Middle)

C/O CONATUS PHARMACEUTICALS INC., 16745 W. BERNARDO DRIVE, SUITE 200

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Vice President, Finance /

(Street)

SAN DIEGO, CA 92127

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4978	I	See footnote. ⁽¹⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	2/16/2021	Common Stock	3636	$0.99	D
Stock Option (Right to Buy)	⁽³⁾	9/18/2023	Common Stock	15000	$9.61	D
Stock Option (Right to Buy)	⁽⁴⁾	2/6/2024	Common Stock	15000	$9.45	D
Stock Option (Right to Buy)	⁽⁵⁾	2/22/2025	Common Stock	15000	$6.40	D
Stock Option (Right to Buy)	⁽⁶⁾	2/3/2026	Common Stock	15000	$1.85	D
Stock Option (Right to Buy)	⁽²⁾	2/3/2026	Common Stock	3750	$1.85	D
Stock Option (Right to Buy)	⁽⁷⁾	3/23/2026	Common Stock	20000	$2.09	D
Stock Option (Right to Buy)	⁽⁸⁾	1/25/2027	Common Stock	23000	$4.21	D

Explanation of Responses:
(1)	Held by family trust of which the Reporting Person is a trustee.
(2)	Immediately exercisable.
(3)	The option was granted on September 19, 2013. 25% of the total number of shares of common stock subject to the option vested on September 19, 2014, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(4)	The option was granted on February 7, 2014. 25% of the total number of shares of common stock subject to the option vested on February 7, 2015, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(5)	The option was granted on February 23, 2015. 25% of the total number of shares of common stock subject to the option vested on February 23, 2016, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(6)	The option was granted on February 4, 2016. 25% of the total number of shares of common stock subject to the option vested on February 4, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(7)	The option was granted on March 24, 2016. 25% of the total number of shares of common stock subject to the option vested on March 24, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(8)	The option was granted on January 26, 2017. 25% of the total number of shares of common stock subject to the option will vest on January 26, 2018, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
VANDERTIE MICHELLE L C/O CONATUS PHARMACEUTICALS INC. 16745 W. BERNARDO DRIVE, SUITE 200 SAN DIEGO, CA 92127			Vice President, Finance

Signatures
/s/ Michelle L. Vandertie		4/7/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.